Efficacy and Safety of Anti-angiogenic Drug Monotherapy and Combination Therapy for Ovarian Cancer: a Meta-analysis and Trial Sequential Analysis of Randomized Controlled Trials

Overview

Journal Front Pharmacol

Date 2024 Jun 11

PMID 38860165

Authors

Yao Xie

Fei Zhou

Affiliations

Soon will be listed here.

Abstract

Background: As the development of novel anti-angiogenic drugs and the continuous evolution of guideline recommendations, the efficacy and safety of anti-angiogenic agents in ovarian cancer (OC) remains unclear. Consequently, a meta-analysis was carried out to assess the efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for OC.

Methods: An exhaustive literature review was performed across multiple databases, including PubMed, Embase, Web of Science, and Cochrane, encompassing all relevant randomized controlled trials (RCTs) up until 6 April 2024. The evaluation of efficacy outcomes incorporated progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). Safety was assessed through the occurrence of any grade adverse events (AEs) and grade ≥3 AEs. Synthesis of the data involved the calculation of hazard ratios (HRs), relative risks (RRs), and their corresponding 95% confidence intervals (CIs) and prediction intervals (PIs). Trial sequential analysis was executed employing TSA v0.9.5.10 Beta software, STATA 12.0, and R software 4.3.1.

Results: In this meta-analysis, 35 RCTs were included, encompassing 16,199 subjects in total. The overall analysis indicated that anti-angiogenic drug combination therapy significantly improved PFS (HR [95% CI] = 0.678 [0.606-0.759], 95% PI: 0.415-1.108), OS (HR [95% CI] = 0.917 [0.870-0.966], 95% PI: 0.851-0.984), and ORR (RR [95% CI] = 1.441 [1.287-1.614], 95% PI: 1.032-2.014), but also increased the incidence of grade ≥3 AEs (RR [95% CI] = 1.137 [1.099-1.177], 95% PI: 1.011-1.252). The analysis did not corroborate any benefit of anti-angiogenic monotherapy over placebo concerning PFS (HR [95% CI] = 0.956 [0.709-1.288], 95% PI: 0.345-2.645) and OS (HR [95% CI] = 1.039 [0.921-1.173], 95% PI: 0.824-1.331). However, it was observed that monotherapy with anti-angiogenic drugs did increase the incidence of any grade AEs (RR [95% CI] = 1.072 [1.036-1.109], 95% PI: 0.709-1.592).

Conclusion: Our study confirmed the PFS, OS, and ORR benefits of anti-angiogenic drug combination therapy for OC patients. The efficacy results of anti-angiogenic monotherapy necessitates further evaluation as more RCTs become available. Clinicians should be vigilant of AEs when administering anti-angiogenic agents in a clinical setting.

Citing Articles

The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities.

Garlisi B, Lauks S, Aitken C, Ogilvie L, Lockington C, Petrik D Curr Oncol. 2024; 31(7):3826-3844.

PMID: 39057155 PMC: 11275383. DOI: 10.3390/curroncol31070283.

References

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G . Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014; 32(13):1302-8. DOI: 10.1200/JCO.2013.51.4489. View

Kim J, Mahner S, Wu L, Shoji T, Kim B, Zhu J . Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study. Int J Gynecol Cancer. 2015; 28(1):2-10. DOI: 10.1097/IGC.0000000000000602. View

Oza A, Cook A, Pfisterer J, Embleton A, Ledermann J, Pujade-Lauraine E . Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015; 16(8):928-36. PMC: 4648090. DOI: 10.1016/S1470-2045(15)00086-8. View

Duska L, Petroni G, Varhegyi N, Brown J, Jelovac D, Moore K . A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol. 2020; 157(3):585-592. DOI: 10.1016/j.ygyno.2019.10.014. View

Yi S, Zeng L, Kuang Y, Cao Z, Zheng C, Zhang Y . Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis. Onco Targets Ther. 2017; 10:973-984. PMC: 5322854. DOI: 10.2147/OTT.S119879. View

Garzon S, Lagana A, Casarin J, Raffaelli R, Cromi A, Franchi M . Secondary and tertiary ovarian cancer recurrence: what is the best management?. Gland Surg. 2020; 9(4):1118-1129. PMC: 7475365. DOI: 10.21037/gs-20-325. View

El Helali A, Wong C, Choi H, Chan W, Dickson N, Siu S . A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer. Sci Rep. 2022; 12(1):3803. PMC: 8907284. DOI: 10.1038/s41598-022-07731-1. View

Herzog T, Scambia G, Kim B, Lhomme C, Markowska J, Ray-Coquard I . A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecol Oncol. 2013; 130(1):25-30. DOI: 10.1016/j.ygyno.2013.04.011. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

10.

du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N . Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2015; 17(1):78-89. DOI: 10.1016/S1470-2045(15)00366-6. View

11.

Khalique S, Banerjee S . Nintedanib in ovarian cancer. Expert Opin Investig Drugs. 2017; 26(9):1073-1081. DOI: 10.1080/13543784.2017.1353599. View

12.

Teleanu R, Chircov C, Grumezescu A, Teleanu D . Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment. J Clin Med. 2020; 9(1). PMC: 7020037. DOI: 10.3390/jcm9010084. View

13.

Vergote I, Bois A, Floquet A, Rau J, Kim J, Del Campo J . Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2019; 155(2):186-191. DOI: 10.1016/j.ygyno.2019.08.024. View

14.

Hall M, Dehbi H, Banerjee S, Lord R, Clamp A, Ledermann J . A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol. 2020; 159(3):692-698. DOI: 10.1016/j.ygyno.2020.09.048. View

15.

Bohndiek S, Sasportas L, Machtaler S, Jokerst J, Hori S, Gambhir S . Photoacoustic Tomography Detects Early Vessel Regression and Normalization During Ovarian Tumor Response to the Antiangiogenic Therapy Trebananib. J Nucl Med. 2015; 56(12):1942-7. PMC: 5612481. DOI: 10.2967/jnumed.115.160002. View

16.

Mei C, Gong W, Wang X, Lv Y, Zhang Y, Wu S . Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine. Front Pharmacol. 2023; 14:1147717. PMC: 10027942. DOI: 10.3389/fphar.2023.1147717. View

17.

Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C . Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol. 2021; 22(2):267-276. DOI: 10.1016/S1470-2045(20)30637-9. View

18.

Ionescu C, Berindan-Neagoe I, Burz C, Balacescu O, Balacescu L, Tudoran O . The clinical implications of platelet derived growth factor B, vascular endothelial growth factor and basic fibroblast growth factor in colorectal cancer. J BUON. 2011; 16(2):274-6. View

19.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

20.

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View